Structured population data were available for 2 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

3 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, unknown_unresolved.

1 supporting study lacks usable structured population information.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

Not applicable to this study design or comparison.

Source evidence could not be resolved sufficiently for this field.

Available source content was suppressed because validation identified a conflict.

Not extracted from the authoritative source.

Clinician-reference record is usable with limitations in: design, risk_of_bias.

Participants switched from premixed insulin to iDegLira for 24 weeks.

iDegLira Treatment Arm

We conducted a 24-week single-arm prospective study to evaluate the impact of iDegLira compared to premixed insulin on the regulation of diabetes and glucovariability using continuous glucose monitoring (CGM), HbA1c, and anthropometric measurements.

Authoritative quality diagnostic: invalid or missing timepoint.

Authoritative quality diagnostic: source evidence unresolved.

iDegLira improves glycemic control in type 2 diabetes

Not reported in the authoritative source.

MDI group

Clinician-reference record is usable with limitations in: population.

Initiation of once daily iGlarLixi plus lifestyle education

iGlarLixi group

Continuation with multiple daily injections (MDI) insulin regimen

iGlarLixi improves glycemic control and reduces insulin injections in type 2 diabetes

Placebo

Core clinician-reference fields are available or not applicable.

Participants received lixisenatide as part of the intervention for 24 weeks.

Lixisenatide

Participants were randomised by means of a computer-generated random sequence to either lixisenatide 10 mcg once daily increased to 20 mcg after 2 weeks or placebo.

Participants received a placebo treatment for 24 weeks.

Authoritative quality diagnostic: invalid or missing value.

Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) × HbA1c

Available supporting studies

iDegLira improves glycemic control in type 2 diabetes

iGlarLixi improves glycemic control and reduces insulin injections in type 2 diabetes

Lixisenatide shows no significant effect on arterial stiffness in diabetes.